Although heart cells and skin cells contain identical instructions for creating proteins encoded in their DNA, they're able ...

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue. Now, researchers at UC San Francisco have found ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences uncovered a new tumor-suppressive response that could lead to novel ...

Akari Therapeutics is advancing its research on a novel spliceosome modulator, PH1, which has shown potential in killing cancer cells and activating the immune system. The company is focusing on the ...

Akari Therapeutics has announced the issuance of Patent No. 562,919 for its PH1 payload, a differentiated spliceosome inhibitor aimed at disrupting RNA splicing to induce cancer cell death and ...